drugset / Trial / NCT07020819
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Timeline
- Start
- 2025-09-12
- Primary completion
- 2026-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANX005 | Protein / enzyme biologic | 30 mg/kg | Intravenous |